Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and ...

We recently published a list of 10 Jim Cramer Stocks to Watch Amid Trump Tariff Wars. In this article, we are going to take a ...

Shares of Bristol Myers Squibb Co. BMY shed 1.18% to $49.61 Thursday, on what proved to be an all-around great trading ...

One big pharma name stands out as an exceptional opportunity: Bristol Myers Squibb ( BMY 1.61%). The stock has been pummeled ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

This revenue marks a 6% decline year-over-year from the same timeframe last year, during which the company recorded a loss of ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.71, a high ...

Bristol-Myers Squibb is undervalued with a 5%+ dividend yield, robust pipeline, and recession-resistant business. Click here ...

Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...

Bill Strazzullo, Bell Curve Trading chief market strategist, said in a latest program on CNBC that the market isn’t done ...

Bristol Myers Squibb & Co (NYSE:BMY) reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 ...

This was the stock's third consecutive day of gains.